{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+antipsychotics&page=2",
    "query": {
      "intervention": "Oral antipsychotics",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+antipsychotics&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T02:47:16.791Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03121586",
      "title": "Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Pimavanserin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ACADIA Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 995,
      "start_date": "2017-01",
      "completion_date": "2024-05-30",
      "has_results": true,
      "last_update_posted_date": "2025-08-24",
      "last_synced_at": "2026-09-28T02:47:16.791Z",
      "location_count": 32,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 27 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Culver City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03121586"
    },
    {
      "nct_id": "NCT02281773",
      "title": "A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "BI 409306 100 mg QD",
          "type": "DRUG"
        },
        {
          "name": "BI 498306 50 mg QD",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "BI 498306 25 mg QD",
          "type": "DRUG"
        },
        {
          "name": "BI 409306 10 mg QD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 518,
      "start_date": "2014-11-10",
      "completion_date": "2016-06-13",
      "has_results": true,
      "last_update_posted_date": "2017-10-19",
      "last_synced_at": "2026-09-28T02:47:16.791Z",
      "location_count": 24,
      "location_summary": "Little Rock, Arkansas • Cerritos, California • Garden Grove, California + 18 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02281773"
    },
    {
      "nct_id": "NCT01760993",
      "title": "Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "SPD489",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 2,
      "start_date": "2013-02-01",
      "completion_date": "2013-04-01",
      "has_results": true,
      "last_update_posted_date": "2021-06-22",
      "last_synced_at": "2026-09-28T02:47:16.791Z",
      "location_count": 2,
      "location_summary": "Oklahoma City, Oklahoma • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01760993"
    },
    {
      "nct_id": "NCT06245213",
      "title": "A Study of ANAVEX3-71 in Adults With Schizophrenia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "ANAVEX3-71 oral capsules",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Anavex Life Sciences Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 71,
      "start_date": "2024-03-15",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-05-04",
      "last_synced_at": "2026-09-28T02:47:16.791Z",
      "location_count": 1,
      "location_summary": "Marlton, New Jersey",
      "locations": [
        {
          "city": "Marlton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06245213"
    },
    {
      "nct_id": "NCT02431702",
      "title": "A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia",
        "Psychotic Disorders"
      ],
      "interventions": [
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        },
        {
          "name": "Haloperidol",
          "type": "DRUG"
        },
        {
          "name": "Olanzapine",
          "type": "DRUG"
        },
        {
          "name": "Oral Paliperidone ER",
          "type": "DRUG"
        },
        {
          "name": "Perphenazine",
          "type": "DRUG"
        },
        {
          "name": "Quetiapine",
          "type": "DRUG"
        },
        {
          "name": "Oral Risperidone",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone Palmitate Injection (PP1M)",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone Palmitate Injection (PP3M)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Scientific Affairs, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 337,
      "start_date": "2015-07-08",
      "completion_date": "2019-11-12",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-09-28T02:47:16.791Z",
      "location_count": 34,
      "location_summary": "Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 31 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Lemon Grove",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02431702"
    },
    {
      "nct_id": "NCT06433635",
      "title": "Sequential Multiple Assignment Randomized Trial for Bipolar Depression",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bipolar I Disorder",
        "Depression"
      ],
      "interventions": [
        {
          "name": "Cariprazine",
          "type": "DRUG"
        },
        {
          "name": "Aripiprazole/Escitalopram combination",
          "type": "DRUG"
        },
        {
          "name": "Quetiapine",
          "type": "DRUG"
        },
        {
          "name": "Lurasidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 2726,
      "start_date": "2024-10-01",
      "completion_date": "2030-02-28",
      "has_results": false,
      "last_update_posted_date": "2025-12-16",
      "last_synced_at": "2026-09-28T02:47:16.791Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Bloomington, Indiana • Baltimore, Maryland + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bloomington",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Belmont",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06433635"
    },
    {
      "nct_id": "NCT01004354",
      "title": "Vitamin D Supplementation in Psychiatric Illnesses",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity",
        "Vitamin D Deficiency",
        "Psychosis",
        "Schizophrenia",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "Ergocalciferols",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Massachusetts, Worcester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "10 Years to 18 Years"
      },
      "enrollment_count": 12,
      "start_date": "2009-06",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2017-11-06",
      "last_synced_at": "2026-09-28T02:47:16.791Z",
      "location_count": 1,
      "location_summary": "Worcester, Massachusetts",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01004354"
    },
    {
      "nct_id": "NCT04860830",
      "title": "CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Iclepertin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 609,
      "start_date": "2021-08-09",
      "completion_date": "2024-11-20",
      "has_results": true,
      "last_update_posted_date": "2026-02-06",
      "last_synced_at": "2026-09-28T02:47:16.791Z",
      "location_count": 24,
      "location_summary": "Anaheim, California • Culver City, California • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pico Rivera",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04860830"
    },
    {
      "nct_id": "NCT02019329",
      "title": "A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "RO5545965",
          "type": "DRUG"
        },
        {
          "name": "risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 32,
      "start_date": "2014-01",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-09-28T02:47:16.791Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02019329"
    },
    {
      "nct_id": "NCT05857566",
      "title": "Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug-induced Weight Gain"
      ],
      "interventions": [
        {
          "name": "RDX-002",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Response Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 24,
      "start_date": "2023-05-16",
      "completion_date": "2023-09-13",
      "has_results": false,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-09-28T02:47:16.791Z",
      "location_count": 1,
      "location_summary": "Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05857566"
    }
  ]
}